Ozempic Weight Loss Ads; New Dietary Guidelines; More Type 1.5 Diabetes DiagnosesOzempic Weight Loss Ads; New Dietary Guidelines; More Type 1.5 Diabetes Diagnoses
(MedPage Today) — Due to sponsored search results — a form of online advertising — the Ozempic formulation of semaglutide appears in Google searches for weight loss, despite not being FDA-approved for this indication. (NPR) New analyses… (MedPage Today) — Due to sponsored search results — a form of online advertising — the Ozempic Read More
T-DXd Moves Into Curative Setting in HER2-Positive Breast CancerT-DXd Moves Into Curative Setting in HER2-Positive Breast Cancer
(MedPage Today) — The DESTINY-Breast11 (DB-11) and DESTINY-Breast05 (DB-05) trials, presented at the European Society for Medical Oncology (ESMO) congress, showed that the inclusion of neoadjuvant or adjuvant trastuzumab pathologic complete response…
Investigational GLP-1-Based Drug Hits MASH Resolution Mark, Misses Fibrosis TargetInvestigational GLP-1-Based Drug Hits MASH Resolution Mark, Misses Fibrosis Target
(MedPage Today) — WASHINGTON — Treatment with the investigational GLP-1/glucagon dual receptor agonist pemvidutide led to resolution of metabolic dysfunction-associated steatohepatitis (MASH) without worsening of fibrosis, but did not improve… (MedPage Today) — WASHINGTON — Treatment with the investigational GLP-1/glucagon dual receptor agonist pemvidutide led to resolution of metabolic dysfunction-associated steatohepatitis (MASH) without worsening Read More
GLP-1 drugs linked to dramatically lower death rates in colon cancer patientsGLP-1 drugs linked to dramatically lower death rates in colon cancer patients
A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists—the class of drugs behind Ozempic, Wegovy and Mounjaro, for example—may do more than regulate blood sugar and weight. In an analysis of more than 6,800 colon cancer patients across all University of California Health sites, researchers found that Read More
Common Everyday Meds Linked to Worse Outcomes in Breast Cancer PatientsCommon Everyday Meds Linked to Worse Outcomes in Breast Cancer Patients
(MedPage Today) — Use of proton pump inhibitors (PPIs) alongside anti-cancer agents was associated with worse survival outcomes in patients with breast cancer, according to an observational study.
Using pooled patient data from 19 breast cancer…
Semaglutide’s MASH Benefits Extend Beyond Weight LossSemaglutide’s MASH Benefits Extend Beyond Weight Loss
(MedPage Today) — WASHINGTON — Semaglutide (Wegovy) improved liver inflammation and fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) through both weight loss-related and direct biological effects, according… (MedPage Today) — WASHINGTON — Semaglutide (Wegovy) improved liver inflammation and fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) through both weight loss-related and direct biological Read More
Weight loss drug could help avoid need for follow-up bariatric surgeryWeight loss drug could help avoid need for follow-up bariatric surgery
Combining bariatric surgery with weight loss medication can help people who need to lose more weight post-surgery, Monash University and Alfred Health-led research has found.
Depression risk higher among long-term breast cancer survivors than women without breast cancer historyDepression risk higher among long-term breast cancer survivors than women without breast cancer history
Long-term breast cancer survivors have a higher risk for developing depression, particularly if they have insomnia, according to a study published online Oct. 10 in SLEEPJ.
Father–son team integrates AI into cancer researchFather–son team integrates AI into cancer research
For more than three decades, USF Distinguished University Professor Dmitry Goldgof in the Bellini College of Artificial Intelligence, Cybersecurity and Computing has been at the forefront of artificial intelligence research. His son, Dr. Gregory Goldgof, is a physician scientist at Memorial Sloan Kettering Cancer Center in New York City, where he serves as the director of Artificial Intelligence for Hematopathology. Trained in both computer science and medicine, Goldgof leads a translational AI laboratory developing deep learning tools to analyze diseases of the blood and bone marrow.
Antibody-Drug Conjugate Shows Benefits in HER2-Positive Early Breast CancerAntibody-Drug Conjugate Shows Benefits in HER2-Positive Early Breast Cancer
(MedPage Today) — The addition of neoadjuvant trastuzumab deruxtecan (T-DXd; Enhertu) significantly improved pathologic complete response (pCR) rates compared with anthracycline-containing chemotherapy in high-risk, HER2-positive early breast…